Hotgen Biotech Ranks on the "2026 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation" List

On September 17, the Beijing Federation of Industry and Commerce held the 2026 Beijing Top 100 Private Enterprises press conference, officially releasing the "1+3+1" list of Beijing's top 100 private enterprises. With its sustained R&D investment and outstanding independent innovation capabilities in the biopharmaceutical field, Hotgen Biotech was successfully selected for the "2026 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation" list, ranking 72nd.


This evaluation was organized by the Beijing Federation of Industry and Commerce in conjunction with relevant departments, based on the capital's "Four Centers" functional positioning and in light of the development characteristics of Beijing's private economy. The Top 100 Scientific and Technological Innovation list uses enterprise operating revenue, R&D expenses, R&D intensity, and R&D personnel as core indicators, comprehensively considering factors such as lawful and compliant operations and honesty and trustworthiness, and determines the listed enterprises based on the quantified scores of core and auxiliary indicators.

In recent years, while consolidating its core advantages in in vitro diagnostics, Hotgen Biotech has continued to deepen its "Diagnosis + Treatment + Big Health" industrial layout. Through enterprises such as Youngen Biotech, Sungen Biomedical, Yujing Pharmaceutical, Shangjing Zhihyao, and Zhiyuan Biology, it has actively deployed cutting-edge biotechnology fields including nucleic acid drugs, antibody drugs, and AI-innovative drugs, and has achieved multiple First-in-Class innovative results. This selection for the "2026 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation" is a full affirmation of Hotgen Biotech's long-term commitment to independent innovation and deep cultivation of its core biopharmaceutical business. In the future, Hotgen Biotech will continue to practice its corporate mission of "Developing Biotechnology to Benefit Human Health," continue to make breakthroughs in innovative drugs and in vitro diagnostics, and contribute to the high-quality development of the capital's private economy with more innovative achievements.